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a b s t r a c t
The effects of comorbid depression and anxiety were compared to the effects of depression
alone and anxiety alone on pregnancy mood states and biochemistry and on neonatal out-
comes in a large multi-ethnic sample. At the prenatal period the comorbid and depressed
groups had higher scores than the other groups on the depressionmeasure. But, the comor-
bid group had higher anxiety, anger and daily hassles scores than the other groups, and they
had lower dopamine levels. As compared to the non-depressed group, they also reported
more sleep disturbances and relationship problems. The comorbid group also experienced
a greater incidence of prematurity than the depressed, the high anxiety and the non-
depressed groups. Although the comorbid and anxiety groups were lower birthweight
than the non-depressed and depressed groups, the comorbid group did not differ from the
depressed and anxiety groups on birth length. The neonates of the comorbid and depressed
groups had higher cortisol and norepinephrine and lower dopamine and serotonin levels
than the neonates of the anxiety and non-depressed groups as well as greater relative right
frontal EEG. These data suggest that for somemeasures comorbidity of depression and anx-
iety is the worst condition (e.g., incidence of prematurity), while for others, comorbidity is
no more impactful than depression alone.
© 2009 Elsevier Inc. All rights reserved.
1. Introduction
Prenatal depression has been noted to have negative effects on fetal growth and neonatal outcome including a greater
incidence of prematurity and low birthweight (Field et al., 2004; Jesse, Seaver, & Wallace, 2003; Moncuso, Schetter, Rini,
Roesch, & Hobel, 2004). Pregnancy anxiety has also been noted for negative neonatal outcomes including a greater incidence
of low birthweight and prematurity (Rondo et al., 2003). Although some studies have targeted depressed women during
pregnancy andhave reported elevated anxiety and anger scores in thosewomen (Field et al., 2003, 2005), less is known about
the comorbid condition of depression and anxiety during pregnancy and its inﬂuence on fetal and neonatal development.
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Current estimates of the incidence of prenatal depression range from 20% to as high as 40% (Andersson, Sundstrom-
Poromaa, Wulff, Astrom, & Bixo, 2006), higher rates than the recent ﬁgures on postpartum depression (17%). The greater
incidence may explain the increasing focus on prenatal depression effects on the fetus and neonate. In a recent study,
we documented the effects of prenatal depression on prematurity and low birthweight (Field et al., 2004). The prenatally
depressedwomenversus non-depressedwomenhadhigher urinary cortisol levels and lower dopamine and serotonin levels,
and they weremore likely to deliver prematurely and have low birthweight babies. The newborns of the depressedmothers
had higher cortisol levels and lower dopamine and serotonin levels, thus mimicking their mothers’ prenatal levels. The
newborns of depressedmothers also had greater relative right frontal EEG activation and lower vagal tone than the neonates
of non-depressed mothers. Finally, they received lower scores on the Brazelton Neonatal Behavioral Assessment Scale. A
path analysis on the effects of the mothers’ prenatal depression and biochemical proﬁle on their newborns’ gestational
age and birthweight suggested that prenatal depression was predictive of prenatal cortisol and norepinephrine levels and
prenatal cortisol levels, in turn, predicted prematurity and low birthweight. Given that prenatal cortisol contributed to only
28% of the variance, other factors such as infections and illness during pregnancy may have contributed to this prematurity
rate. For example, prolonged sick leave, increased nausea and vomiting and increased number of visits to the obstetrician
have been reported in depressed pregnant women in at least one sample (Andersson, Sundstrom-Poromaa, Wulff, Astrom,
& Bixo, 2004).
Prenatal anxiety effects on the fetus and neonate have included increased uterine artery resistance leading to reduced
blood ﬂow to the fetus (Glover, Teixeira, Gitau, & Fisk, 1999). This same group of investigators also implicated cortisol and
norepinephrine as potential mediators of the effects of anxiety on intrauterine artery resistance and ultimately low birth-
weight (Teixeira, Fisk, & Glover, 1999). Prenatal anxiety is also thought to lead to a greater incidence of low birthweight
and prematurity (Rondo et al., 2003). Elevated anxiety and anxiety disorders during pregnancy have also been associated
with lower apgar scores (Berle et al., 2005). Just as prenatal depression predicts to postnatal depression, and prenatal anx-
iety predicts to postpartum anxiety (Herson et al., 2004), prenatal anxiety in this study was also noted to predict postnatal
depression at 8 weeks and at 8 months. It is perhaps not surprising, then, that prenatal and postnatal anxiety may con-
tribute to colic (Canivet, Ostergren, Rosen, Jakobsson, & Hagander, 2005) as well as more difﬁcult temperament during
later infancy (Austin, Hadzi-Pavlovic, Leader, Saint, & Parker, 2005). And, longer term effects have been noted, for example,
atypical handedness at 42 months (Glover, O’Connor, Heron, Golding, & ALSPAC Study Team, 2004) and behavior prob-
lems at 4 years (O’Connor, Heron, Glover, & ALSPAC Study Team 2002; O’Connor, Heron, Golding, Beveridge, & Glover,
2002).
Although anxiety and depression are thought to be two separate disorders, they occur comorbidly in as many as 30–58%
of patients with major depression disorder (Pollack, 2005; Young, Abelson, & Cameron, 2004). Patients with depression and
comorbid anxiety symptoms versus thosewith depression alone have beennoted to havemore severe depressive symptoms,
longer depressive episodes, a more chronic course, worse psychosocial impairment, a poorer response to medication, less
recovery from the index episode and increased suicidality (Pollack, 2005). The effects may be more than simply additive
even though prenatal depression and prenatal anxiety as individual disorders might be expected to have similar effects on
the fetus and neonate. Some have suggested, however, that anxiety and depression have different effects and that they may
operate by different mechanisms (Glover et al., 1999). Anxiety and depression are more likely to be comorbid than non-
comorbid in pregnant women, and, thus, the effects may combine by still a third mechanism. The more typical condition,
i.e., comorbidity of anxiety and depression may lead to both shorter gestational age and reduced birthweight than either
condition alone. The data from the separate literatures on prenatal depression and prenatal anxiety effects may have been
confounded by this comorbidity.
The purpose of the present study was to explore the separate effects of prenatal depression and anxiety and the effects
of comorbid depression and anxiety on: (1) mothers’ mood states including depression, anxiety and anger and on their daily
hassles and sleep disturbances as well as their EEG and biochemistry (cortisol, norepinephrine, epinephrine, dopamine and
serotonin) at the prenatal and the neonatal periods; and (2) neonatal outcomes including birth measures and the same
biochemical measures and EEG that were taken for the mothers. Comorbid depression and anxiety effects were expected to
be worse than depression or anxiety effects alone.
2. Method
2.1. Participants
Nine-hundred and eleven pregnant women were recruited during their second trimester of pregnancy (M=20 weeks
gestation). The women were assigned to 4 groups based on the Structural Clinical Interview for DSM-IV Disorders as fol-
lows: (1) Non-depressed or No Diagnosis (N=345); (2) Anxiety Disorder (N=77); (3) Depressive Disorder (N=181); and (4)
Comorbid Anxiety-Depressive Disorder (N=308). They were contacted before their ultrasound examination at a large urban
University Hospital. Women were excluded from participation in the study if they (1) were less than 18 years old, (2) had
multiple fetuses and (3) reported HIV/AIDS status or medical complications.
The women were between 18 and 40 years old (M=27.5) and their mean parity was 1.2 with 57% of the sample being
primiparous. The sample was comprised of women with a college (25%) or a high school degree or less (46%). The women
had a predominantly low to middle socioeconomic status (M=3.7 on the Hollingshead Two-factor Index of Social Status).
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Thewomen’s ethnicity was distributed 59% Hispanic, 32% Black and 9% Caucasian. Most of thewomenwere in a relationship
(95%). The 4 groups did not differ on these demographic variables.
2.2. Procedures
The women were recruited at the prenatal clinics of a university hospital by trained female interviewers. The women
who expressed interest in participating in this study (approximately 80%) were asked to sign an informed consent and
to participate in approximately one hour of assessments. Then the women were interviewed to obtain demographic data,
and they were given the SCID for a diagnosis, as well as the Center for Epidemiological Studies-Depression scale (CES-D)
(Radloff, 1977), the State Anxiety Inventory (STAI) (Spielberger, Gorsuch, & Lushene, 1970), the State Anger Inventory (STAXI)
(Spielberger, Ritterband, Sydeman, Reheiser, & Unger, 1995), the Behavioral Inhibition Scale (BIS) (Carver & White, 1994)
the Daily Hassles Scale (Field et al., 2003), the Sleep Disturbance Scale (Verran & Snyder-Halpern, 1988) and the Relationship
Questionnaire (Figuereido, Field, Hernandez-Reif, & Diego, 2007). The women also provided a urine sample to be assayed
for cortisol and the metabolites of norepinephrine, epinephrine, dopamine and serotonin.
2.3. Instruments
Structured Clinical Interview for DSM-IV Disorders (SCID): All women in the study were given the SCID (research version)
to determine depression and anxiety diagnoses and to screen out other disorders including bipolar disorder, schizophrenia
and other psychotic disorders. Thewomenwhowere diagnosedwith Dysthymia orMajor Depression or Anxiety Disorder on
the SCID based on DSM IV symptoms and mothers who were free of any diagnosis (the non-depressed group) were eligible
for the study. The SCID was administered by female research associates following training and with continuing supervision
by a clinical psychologist. Almost all of the depressed pregnant women (98%) were not taking anti-depressants and were
not receiving other treatments for depression.
The Center for Epidemiology Studies-Depression Scale (CES-D) is a 20-item scale that assesses the frequency of depressive
symptoms within the last week. With scores ranging from 0 to 60, a cut-off score of 16 is used for classifying a major
depressive episode. With only a 6% false positive and 36% false negative rate (Myers & Weissman, 1980), this scale has been
shown to be reliable and valid for diverse demographic groups (Radloff, 1977) and has been successfully used as a self-report
assessment of depression in a number of studies that involved similar populations (Diego et al., 2004).
The State Anxiety Inventory (STAI) is comprised of 20 items and assesses the intensity of anxiety symptoms. The scores
range from 20 to 90, and the cut-off for high anxiety is 48. Research has demonstrated that the STAI has adequate concurrent
validity and internal consistency (Spielberger et al., 1970), and the scale has been used in several studies with pregnant
women (e.g., Da Costa, Larouche, Dritsa, & Brender, 2000).
State Anger Inventory (STAXI) (Spielberger, Ritterband, Sydeman, Reheiser, & Unger, 1995) is a 10-item inventory that
assesses general feelings of anger based on a 4-point Likert scale ranging from 1 (almost never) to 4 (almost always). Typical
questions include “I am quick tempered” and “I ﬂy off the handle”. Psychometric properties have been established for the
STAXI on diverse ethnic groups including a test–retest reliability coefﬁcient of 0.97.
The Behavioral Inhibition Scale (BIS) (Carver & White, 1994): The BIS is a 24-item questionnaire consisting of personal
statements followed by 4 severity options ranging from very true to very false. Scores can range from 24 to 96. The BIS is
designed to assess the tendency to behave in response to reward or in response to punishment. High Behavioral Inhibition
System (BIS) scores reﬂect withdrawal behavior.
Daily Hassles Scale (Field et al., 2003): This scale was developed to assess the degree of hassle being experienced by
expectant mothers. The 16 items on a 4-point Likert scale include questions on people such as family members, landlord
and friends and ﬁnances creating hassles.
Sleep Disturbance Scale (Verran & Snyder-Halpern, 1988): Questions on this 15-item scale are rated on a visual analogue
anchored at one end with effective sleep responses (e.g., “Did not awaken,” “Had no trouble sleeping”) and at the opposite
end with ineffective responses (e.g., “Was awake 10h,” “Had a lot of trouble falling asleep”). The participants place a mark
across the answer line at the point that best reﬂects their last night’s sleep. A reliability coefﬁcient of .82 has been reported
for this scale. The sleep disturbance subscale was used in this study.
The Relationship Questionnaire (Figuereido et al., 2007) is comprised of 12 items on a 4-point Likert scale and is focused
on positive and negative aspects of spouse/partner relationships. The positive dimensions include a sense of support and
care, as well as satisfaction, closeness and joint interests and activities, and the negative dimensions include, for example,
anxiety, irritability and criticisms that have been associatedwith undesirable outcomes. Data for thismeasurewere available
for 95% of the sample (95% of the women being in relationships with a spouse or partner).
Pregnancy Stress Questions (Field, 2007): This questionnaire includes 3 questions that address pregnancy stress including;
“Have you had any stressful situations during pregnancy”, “Are you unhappy about being pregnant?”, and “Is your partner
unhappy about being pregnant?”.
Urinary catecholamines andmetabolites: Urinary sampleswere collectedmid-morning from thewomenat thebeginningof
the 20 and 32week gestation visits and from the neonates within the ﬁrst two days post-delivery. No systematic differences
were noted in the sampling or the timing of collection of urine samples between women. Urine samples were transferred to
plastic vials and frozenwithout using acid or other preservatives and shipped to Duke UniversityMedical School. The assays
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Table 1
Means for prenatal self-report variables for non-depressed, anxiety, depressed and comorbid depression and anxiety groups (S.D. in parentheses). Different
letter superscripts denote differences between group means.
Group
Non-depressed Anxiety Depressed Comorbid F p
Measures
Prenatal early GA (20 weeks)
Depression (CES-D) 8.45a (3.84) 10.51b (3.71) 22.11c (5.96) 27.15c (7.60) 661.37 .000
Anxiety (STAI) 30.74a (5.06) 45.57b (5.16) 33.85c (5.27) 50.18d (7.07) 694.14 .000
Anger (STAXI) 15.96a (4.14) 18.12b (4.51) 19.58b (6.20) 22.18c (6.05) 62.72 .000
Behavioral inhibition (BIS) 17.66a (3.55) 18.15ab (3.31) 18.46ab (4.30) 18.63b (3.78) 3.37 .02
Daily Hassles 19.31a (5.48) 22.91b (5.41) 22.77b (7.87) 27.50c (7.63) 46.28 .000
Sleep disturbances 37.60a (22.61) 44.80ab (13.38) 44.09ab (24.66) 48.02b (20.82) 2.90 .04
Relationships 2.21a (0.88) 1.33ab (0.94) 1.04ab (1.07) 0.78b (1.18) 2.93 .05
Prenatal late GA (32 weeks)
Depression (CES-D) 11.70a (7.20) 12.18a (6.92) 17.29b (10.26) 19.37b (9.08) 7.78 .000
Anxiety (STAI) 37.91a (9.05) 37.06a (10.27) 41.69ab (9.72) 44.75b (9.66) 5.53 .001
Anger (STAXI) 16.35 (4.44) 17.22 (5.36) 19.44 (8.01) 19.64 (7.46) 2.06 .11
Daily Hassles 19.50a (5.71) 24.00b (5.23) 24.00b (5.41) 28.50c (4.24) 14.62 .03
Sleep disturbances 40.48a (21.89) 48.60ab (21.47) 46.63ab (20.61) 54.93b (19.18) 4.14 .008
Postnatal (2 days)
Depression (CES-D) 10.49a (7.35) 12.94ab (7.65) 15.95b (9.01) 21.22c (10.26) 46.52 .000
Anxiety (STAI) 32.22a (6.59) 40.70b (8.01) 34.40a (7.61) 43.89bc (10.58) 58.90 .000
Anger (STAXI) 15.80a (4.45) 18.45b (4.71) 17.49b (5.97) 19.40c (5.26) 13.92 .000
Sleep disturbances 47.12 (20.37) 43.45 (20.75) 41.01 (12.53) 58.91 (14.62) 2.13 .11
were conducted by high-pressure liquid chromatography with electrochemical detection (Kilts, Gooch, & Knopes, 1984).
Urinary levels of the norepinephrine, dopamine, and serotonin metabolites were measured, as the majority of excreted
catecholamines and serotonin respectively exist in the form of metabolites. Urinary cortisol was assayed in the stored urine
samples by radioimmunoassay using a speciﬁc antiserum from Radioassay Systems Laboratories (Carson City, CA). Bound
and free hormones are separated by the dextran-coated charcoal technique. The sensitivity of the assay is 0.025ng/tube.
The inter-assay and intra-assay coefﬁcient of variation is less than 10% and 5% respectively. All values were corrected for
creatinine volume. The elution of cortisol and the internal standard were then done on a reverse phase chromatographic
system (Bondapak C column and methanol:water mobile phase).
These assays were conducted because in at least two other samples we have noted increased cortisol and decreased
metabolites of dopamine and serotonin in depressed pregnant women and their newborns (Field et al., 2004; Lundy et
al., 1999). Similarly, Glover et al. (1999) have reported elevated levels of cortisol and norepinephrine in pregnant women
with high anxiety levels. Thus, we would expect the comorbid group to have higher levels than the depressed and anxiety
groups.
3. Results
As can be seen in Table 1, on the self-report measures: (1) for the prenatal early gestation (20 weeks) period, separate
ANOVAswith group as the independentmeasure and each of the self-report scales as the dependentmeasures revealed that
the comorbid group had (a) similar depression (CES-D) scores as the depressed group but worse depression scores than the
other groups; (b) worse scores than all groups for anxiety (STAI), anger (STAXI) and Daily Hassles; and (c) worse than the
non-depressed group but the same as the depressed and anxiety groups on sleep disturbances, relationships and behavioral
inhibition scales; and (2) for the prenatal late gestation (32 weeks) period, separate ANOVAs suggested that the comorbid
group had: (a) worse scores than the other groups for depression and anger; and (b) similar scores as the anxiety group on
anxiety but, in turn, worse anxiety scores than the other groups.
As can be seen in Table 2, ANOVAs on the biochemistry variables revealed the following: (1) the lowest dopamine levels
at both the early and late gestational age periods for the comorbid groupmothers; (2) the highest epinephrine levels for the
comorbid group mothers at the postnatal period; and (3) higher cortisol and norepinephrine levels in the newborns of the
comorbid and depressed mothers and lower dopamine and serotonin levels in those groups of newborns.
The separate ANOVAs on neonatal outcome variables (Table 3) suggest that the newborns of the comorbid group: (1) had
a greater incidence of prematurity than the other groups; (2) had lower birthweight and birth length than the neonates of
the non-depressed mothers, but the neonates of the comorbid mothers were equivalent to the neonates of the depressed
mothers on birth length and to the neonates of the anxiety group on both birthweight and birth length; (3) the comorbid
depressed/anxiety mothers had greater relative right frontal EEG activation than the non-depressedmothers, but they were
equivalent to the mothers in the depressed and anxiety groups; and (4) the neonates of the comorbid group mothers had
greater relative right frontal EEG activation than the neonates of the non-depressed and anxiety mothers, although they
were equivalent to the neonates of the depressed mothers.
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Table 2
Means for biochemical variables (in ng/ml) for non-depressed, anxiety, depressed and comorbid depression and anxiety groups (S.D. in parentheses).
Different letter superscripts denote differences between group means.
Group
Non-depressed Anxiety Depressed Comorbid F p
Measures
Prenatal early GA (20 weeks)
Cortisol 200.74 (114.12) 173.64 (119.88) 197.11 (123.60) 200.76 (112.20) NS
Norepinephrine 52.00 (23.10) 63.95 (27.44) 55.75 (25.48) 59.93 (25.24) 1.93 .12
Epinephrine 4.74 (3.18) 5.90 (2.83) 5.31 (4.73) 5.93 (4.00)
Dopamine 287.49a (114.93) 361.91b (176.73) 272.89ac (114.11) 265.41c (124.83) 3.38 .02
Serotonin 3993.20 (2071.66) 4595.07 (2316.06) 3882.18 (2045.36) 4026.63 (2470.32) NS
Prenatal late GA (32 weeks)
Cortisol 190.04 (100.64) 200.71 (181.71) 168.82 (86.89) 219.81 (142.09) NS
Norepinephrine 45.32a (30.24) 63.06b (18.00) 45.41a (19.86) 54.58b (28.88) NS
Epinephrine 3.35a (3.41) 4.08b (3.20) 2.62c (1.05) 4.03b (3.49) NS
Dopamine 189.69a (109.52) 275.64b (99.37) 196.42a (116.43) 159.07c (144.07) 3.03 .05
Serotonin 2638.01 (1783.53) 4358.87 (2702.63) 2144.77 (1258.73) 2964.10 (1992.86) NS
Postnatal-mother (2 days)
Cortisol 162.30a (96.21) 120.28b (73.19) 228.40c (176.07) 209.73c (184.65) 2.18 .10
Norepinephrine 31.28a (13.700 31.45a (21.01) 39.15b (34.47) 43.37b (29.49) NS
Epinephrine 4.67a (2.93) 2.60b (1.17) 4.59a (1.63) 6.17c (2.11) 2.71 .05
Dopamine 246.85 (89.84) 270.37 (106.87) 232.19 (155.89) 192.95 (105.08) NS
Serotonin 4552.90 (3617.89) 2962.96 (1881.94) 2985.05 (815.44) 4679.32 (2315.05) NS
Neonate
Cortisol 360.58a (230.53) 272.87b (270.44) 469.81c (296.31) 455.38c (262.70) 3.08 .05
Norepinephrine 54.80a (36.10) 60.00ab (102.32) 63.75b (26.15) 62.13b (24.08) 4.25 .009
Epinephrine 29.07 (86.91) 7.02 (7.29) 5.62 (2.93) 5.07 (2.95) NS
Dopamine 530.16a (258.48) 525.68a (486.38) 366.76b (129.36) 395.96b (227.39) 3.80 .05
Serotonin 3909.02a (2088.58) 3459.95a (2463.21) 2204.01b (2106.08) 2553.72b (2142.39) 3.27 .05
Table 3
Means for neonatal outcome variables.
Group
Non-depressed Anxiety Depressed Comorbid F p
Measures
Prematurity (%) 6.0a 10.2b 6.5a 14.5c 11.26 .01
Birthweight 3352.17a (448.26) 3195.76b (347.75) 3355.57a (404.14) 3224.29b (483.42) 4.80 .003
Birth length 50.66a (3.16) 50.40ab (1.40) 50.75ab (3.56) 49.56b (4.96) 2.64 .05
EEG
Mother .02a (.13) −.07ab (.20) −.12ab (.24) −.16b (.19) 4.14 .01
Infant .03a (.10) .10a (.26) −.05b (.15) −.08b (.15) 5.07 .003
Table 4
Means for potential confounding variables.
Group
Non-depressed Anxiety Depressed Comorbid X2 p
Measures
Stressful situation during pregnancy (%) 32.9a 43.3b 43.5b 59.6c 40.07 .000
Unhappy about pregnancy (%) 13.2a 13.4a 25.5b 32.8c 34.53 .000
Partner unhappy about pregnancy (%) 9.1a 10.4a 18.2b 19.5b 14.76 .002
Table 4 results suggest group differences on potential confounding variables including the comorbid group having: (1)
a greater incidence of “a stressful situation during pregnancy” than the other groups; (2) a greater incidence of “being
unhappy about the pregnancy”; and (3) a greater incidence of the partner “being unhappy about the pregnancy”, although
the incidence of the partners being unhappy in the comorbid group was similar to the incidence for the depressed group.
4. Discussion
These data on pregnant women with comorbid depression/anxiety disorder are consistent with data in the literature
on comorbidity in non-pregnant adults (Pollack, 2005; Young et al., 2004), although the pregnant women in this study did
not report more severe depressive symptoms than the depression-only women. They did, however, report more anxiety
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and anger symptoms than the anxiety and depression disorder groups at the early gestation period, although they did not
differ from the depression group at the late gestation period. Although the comorbid group was no worse than the other
disorder groups on the Behavioral Inhibition, Sleep Disturbances and Relationship Scales, they did report more potentially
confounding problems includingmore frequent daily hassles, “stressful situations during pregnancy” andmore often “being
unhappy about the pregnancy”.
Although we did not compare the groups across the early and late gestation periods, the early gestation differences
between the comorbid and depression groups tended to disappear by late gestation except that the comorbid group had the
lowest dopamine levels during the late gestational age period. It is not clear what this means except that dopamine is an
activating transmitter that is notably low in very depressed individuals and may have contributed to the comorbid group
having a greater incidence of prematurity.
The greater incidence of prematurity noted for the neonates of the comorbid group highlights the additive effects of
prenatal depression and anxiety on neonatal outcomes. However, the comorbid group newborns were equivalent to the
anxiety group newborns on their lower birthweight, and they were equivalent to both the anxiety and the depressed group
newborns on their lower birth length. In addition, although the right frontal EEG patterns of the comorbid mothers did not
differ from those of the mothers in the other disorder groups, greater right frontal EEG activation was noted in the neonates
of the comorbid and depressed groups versus the anxiety and non-depressed groups.
Finally, the cortisol and norepinephrine levels of the neonates in the comorbid and depressed groupswere equally higher
than the levels of the newborns in the anxiety and non-depressed groups, and the dopamine and serotonin levels of the
newborns of the comorbid and the depressed mother groups were equally lower than the levels of these neurotransmitters
in the newborns of the high anxiety andnon-depressed groups. Thus, these data suggest that for somemeasures, comorbidity
of depression and anxiety is the worst condition (e.g., a greater incidence of prematurity) while for others, comorbidity is
no more impactful than depression alone or anxiety alone.
It is not clear from these data why comorbid, depression and anxiety would have additive effects given that depres-
sion and anxiety seem to be opposite mood states and would also seemingly be characterized by different biochemical
proﬁles. The comorbid women did not appear to have higher depression scores but they did have higher anxiety, daily
hassles and stress/unhappiness scores. Their dopamine levels were also lower. It is interesting, then, that the comorbid and
anxiety group newborns were equivalent on low birthweight. Low birthweight has been attributed to prenatal anxiety and
intrauterine artery resistance and, indirectly, to elevated norepinephrine (Teixeira et al., 1999). However, in this sample the
prenatal maternal norepinephrine levels were not high in these groups, although the comorbid group neonates had higher
norepinephrine levels.
These complexbiochemicalﬁndings aredifﬁcult to interpret, and they illustrate the limitationsof this study. Themeasures
are indirect. The urinary metabolites are very limited measures of central nervous system metabolites, and the self-report
scales are also indirectmeasures. The interactions of the variousmood states (i.e., depression, anxiety, anger) and the various
biochemical measures are perhaps too complex to measure even in large samples (albeit very unequal N samples) like this.
Nonetheless, these data strongly suggest the need for both behavioral and biochemical studies that identify at-risk proﬁles,
and they highlight the importance of identifying comorbidly depressed and anxious pregnant women as well as women
who are only depressed or only experiencing high anxiety so that they may receive prenatal interventions to lower those
levels.
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